Literature DB >> 21394087

Renal denervation and hypertension.

Markus P Schlaich1, Henry Krum, Paul A Sobotka, Murray D Esler.   

Abstract

Essential hypertension remains one of the biggest challenges in medicine with an enormous impact on both individual and society levels. With the exception of relatively rare monogenetic forms of hypertension, there is now general agreement that the condition is multifactorial in nature and hence requires therapeutic approaches targeting several aspects of the underlying pathophysiology. Accordingly, all major guidelines promote a combination of lifestyle interventions and combination pharmacotherapy to reach target blood pressure (BP) levels in order to reduce overall cardiovascular risk in affected patients. Although this approach works for many, it fails in a considerable number of patients for various reasons including drug-intolerance, noncompliance, physician inertia, and others, leaving them at unacceptably high cardiovascular risk. The quest for additional therapeutic approaches to safely and effectively manage hypertension continues and expands to the reappraisal of older concepts such as renal denervation. Based on the robust preclinical and clinical data surrounding the role of renal sympathetic nerves in various aspects of BP control very recent efforts have led to the development of a novel catheter-based approach using radiofrequency (RF) energy to selectively target and disrupt the renal nerves. The available evidence from the limited number of uncontrolled hypertensive patients in whom renal denervation has been performed are auspicious and indicate that the procedure has a favorable safety profile and is associated with a substantial and presumably sustained BP reduction. Although promising, a myriad of questions are far from being conclusively answered and require our concerted research efforts to explore the full potential and possible risks of this approach. Here we briefly review the science surrounding renal denervation, summarize the current data on safety and efficacy of renal nerve ablation, and discuss some of the open questions that need to be addressed in the near future.

Entities:  

Mesh:

Year:  2011        PMID: 21394087     DOI: 10.1038/ajh.2011.35

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

1.  Heart failure with a normal ejection fraction: treatments for a complex syndrome?

Authors:  Samuel Bernard; Mathew S Maurer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 2.  How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?

Authors:  Kui Toh Gerard Leong; Henry Krum
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

3.  Renal artery denervation for treating resistant hypertension : definition of the disease, patient selection and description of the procedure.

Authors:  Massimo Volpe; Enrico Agabiti Rosei; Ettore Ambrosioni; Santina Cottone; Cesare Cuspidi; Claudio Borghi; Nicola De Luca; Francesco Fallo; Claudio Ferri; Giuseppe Mancia; Alberto Morganti; Maria Lorenza Muiesan; Riccardo Sarzani; Leonardo Sechi; Giuliano Tocci; Agostino Virdis
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-02-19

4.  Renal sympathetic denervation using an externally irrigated radiofrequency ablation catheter for treatment of resistant hypertension - Acute safety and short term efficacy.

Authors:  Sachin Yalagudri; Narayana Raju; Bharati Das; Ashwin Daware; Shreesha Maiya; Kannan Jothiraj; A G Ravikishore
Journal:  Indian Heart J       Date:  2015-05-21

5.  Early life stress sensitizes the renal and systemic sympathetic system in rats.

Authors:  Analia S Loria; Michael W Brands; David M Pollock; Jennifer S Pollock
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-15

6.  Renal Sympathetic Denervation for Treatment of Hypertension.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-02-01

7.  Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Authors:  Valeria Avataneo; Amedeo De Nicolò; Franco Rabbia; Elisa Perlo; Jacopo Burrello; Elena Berra; Marco Pappaccogli; Jessica Cusato; Antonio D'Avolio; Giovanni Di Perri; Franco Veglio
Journal:  Br J Clin Pharmacol       Date:  2018-08-15       Impact factor: 4.335

Review 8.  Renal sympathetic nervous system and the effects of denervation on renal arteries.

Authors:  Arun Kannan; Raul Ivan Medina; Nagapradeep Nagajothi; Saravanan Balamuthusamy
Journal:  World J Cardiol       Date:  2014-08-26

9.  Cardiovascular autonomic response to amlodipine in primary hypertension.

Authors:  Youssouf Radjab; Souad Aboudrar; Fatima Zahra Milouk; Hanan Rkain; Mustapha El Bakkali; Taoufiq Dakka; Leslie Coghlan; Halima Benjelloun
Journal:  ISRN Cardiol       Date:  2012-06-25

10.  Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome.

Authors:  Tetsuji Katayama; Daisuke Sueta; Keiichiro Kataoka; Yu Hasegawa; Nobutaka Koibuchi; Kensuke Toyama; Ken Uekawa; Ma Mingjie; Takashi Nakagawa; Masanobu Maeda; Hisao Ogawa; Shokei Kim-Mitsuyama
Journal:  J Am Heart Assoc       Date:  2013-08-23       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.